Stocks Health care VRDN
NASDAQ · Health careViridian Therapeutics, Inc. (VRDN)
Viridian Therapeutics, Inc. brought in $26.3M of revenue over the twelve months to September 30, 2026, down 62.8% from a year earlier. It posted a net loss of $453.6M. In fiscal 2025 capital spending exceeded operating cash flow by $276.9M. At September 30, 2026 it held $172.9M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 4, 2026.
Key facts about Viridian Therapeutics, Inc.
- Net worth
- Viridian Therapeutics, Inc. has a market value (market cap) of $3.4B at the latest share price, and shareholders' equity of $580.7M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $70.8M (+23,359.9% year on year), with a net loss of $342.6M. Over the 12 months to September 30, 2026: revenue $26.3M, net loss $453.6M.
- Cash flow
- In fiscal 2025 operations used $276.4M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 4, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Viridian Therapeutics, Inc.'s next report is expected around February 25, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Viridian Therapeutics, Inc. does
Viridian Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker VRDN.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $70.8M | -$342.6M | n/a | -$276.9M |
| 2024 | $302K | -$269.9M | n/a | -$232.8M |
| 2023 | $314K | -$237.7M | -$5.31 | -$185.1M |
| 2022 | $1.8M | -$129.9M | -$4.05 | -$94.6M |
| 2021 | $3M | -$79.4M | -$6.66 | -$54.9M |
| 2020 | $1.1M | -$110.7M | -$31.13 | -$29.8M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where VRDN ranks in Health care
Latest SEC filings
What Viridian Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 9, 2026
- November 4, 2026Quarterly report 10-Q · period to September 30, 2026Revenue fell 64% to $25.8M versus the same quarter last year; net loss of $101.2M.
- November 4, 2026
- August 20, 2026Passive stake (5% or more) SCHEDULE 13G
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake (5% or more) SCHEDULE 13G
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 6, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 279% to $284K versus the same quarter last year; net loss of $127.1M.
- August 6, 2026
Insider trades
What the people running Viridian Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $348.2K worth of shares in the last 90 days and bought none on the open market.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| August 19, 2026 | Tousignant JenniferChief Legal Officer | Sold | 4,212 | $103.2K |
| August 19, 2026 | Tousignant JenniferChief Legal Officer | Exercised options | 10,000 | $144.1K |
| August 19, 2026 | Tousignant JenniferChief Legal Officer | Sold | 10,000 | $245K |
| August 14, 2026 | Tripuraneni RadhikaChief Medical Officer | Exercised options | 40,000 | $528.4K |
| May 11, 2026 | Fairmount Funds Management LLCDirector, 10% owner | Boughtindirect | 1,176,470 | $20M |
| March 3, 2026 | Mahoney Stephen F.President and CEO, Director | Shares withheld for tax | 7,408 | $223.6K |
| March 3, 2026 | Tousignant JenniferChief Legal Officer | Shares withheld for tax | 1,675 | $50.6K |
| March 3, 2026 | Beetham Thomas W.Chief Operating Officer | Shares withheld for tax | 3,048 | $92K |
Who owns VRDN
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Fairmount Funds Management LLC13D, may seek influence with 1 related filers | 14.04% | May 13, 2026 |
| Bellevue Group AG13G, passive with 1 related filers | 6.6% | May 15, 2026 |
| Paradigm BioCapital Advisors LP13G, passive with 3 related filers | 6.1% | August 14, 2026 |
| Kynam Capital Management, LP13G, passive with 2 related filers | 5.7% | August 14, 2026 |
| T. Rowe Price Associates, Inc.13G, passive | 5.2% | August 14, 2026 |
| Point72 Asset Management, L.P.13G, passive with 2 related filers | 5% | August 20, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 214 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Fmr LLC | 16,604,740 | +1,225,363 |
| BlackRock, Inc. | 8,551,488 | +720,013 |
| Bellevue Group AG | 6,731,909 | +5,765 |
| Paradigm Biocapital Advisors LP | 6,723,788 | +3,574,895 |
| Kynam Capital Management, LP | 6,453,877 | +4,112,225 |
| State Street Corp | 6,124,976 | +1,452,091 |
| Fairmount Funds Management LLC | 5,090,928 | +1,176,470 |
| Vanguard Capital Management LLC | 4,576,860 | +409,659 |
| Deep Track Capital, LP | 3,592,740 | +2,198,796 |
| Venrock Adviser, LLC | 3,257,917 | -624,792 |
| Wellington Management Group Llp | 3,128,362 | +49,808 |
| Vanguard Portfolio Management LLC | 2,752,827 | +1,111,350 |
| Geode Capital Management, LLC | 2,501,869 | +168,656 |
| Avoro Capital Advisors LLC | 2,500,000 | +1,000,000 |
| Baker Bros. Advisors LP | 2,383,025 | +411,347 |
| Point72 Asset Management, L.P. | 2,343,208 | +2,020,372 |
| Caligan Partners LP | 2,193,981 | new |
| Novo Holdings A/S | 2,135,000 | +135,000 |
| Tang Capital Management LLC | 1,792,626 | 0 |
| Fisher Asset Management, LLC | 1,750,850 | -17,445 |
Insiders
5 insiders reported holding 5,185,488 shares in total, about $160M at the last price.
| Holder | Shares |
|---|---|
| Fairmount Funds Management LLCDirector, 10% owner | 5,090,9285,090,928 held indirectly |
| Tripuraneni RadhikaChief Medical Officer | 40,000 |
| Mahoney Stephen F.President and CEO, Director | 33,349 |
| Beetham Thomas W.Chief Operating Officer | 13,361 |
| Harmon SethChief Financial Officer | 7,850 |
Questions about VRDN
What does Viridian Therapeutics, Inc. do?
Viridian Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as VRDN. Its shares trade on NASDAQ under the ticker VRDN.
What is Viridian Therapeutics, Inc.'s net worth?
Viridian Therapeutics, Inc. has a market value (market cap) of $3.4B at the latest share price, and shareholders' equity of $580.7M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Viridian Therapeutics, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $453.6M on revenue of $26.3M.
How much revenue does Viridian Therapeutics, Inc. make?
Over the twelve months to September 30, 2026 Viridian Therapeutics, Inc. reported revenue of $26.3M. That is 62.8% less than a year earlier.
When did Viridian Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 4, 2026. It covers the period to September 30, 2026. Its newest filing of any kind is the investor disclosure from November 9, 2026.
When is Viridian Therapeutics, Inc.'s next earnings report?
Viridian Therapeutics, Inc.'s next report is expected around February 25, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare VRDN with
Follow VRDN
Get an email when Viridian Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Viridian Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.